Ravi Shankar Prasad Singh

Pfizer Inc. - New York / United States

Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences

AD Scientific Index ID: 4389827

-

Go Premium -
Unlock Full Profile Tools

Get Your Global Impact Certificate

Ravi Shankar Prasad Singh's MOST POPULAR ARTICLES

1-) An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 Science 374 (6575), 1586-1593, 2021

2-) Comparison of various international guidelines for analytical method validation Die Pharmazie-An International Journal of Pharmaceutical Sciences 62 (1), 4-14, 2007

3-) Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID‐19 trial of nirmatrelvir Clinical Pharmacology & Therapeutics 112 (1), 101-111, 2022

4-) Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans Drug Metabolism and Disposition 50 (5), 576-590, 2022

5-) Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple … Arthritis research & therapy 21 (1), 1-17, 2019

ARTICLES

Add your articles